Boehringer antes up on a €627.5M deal for rights to Autifony’s schizophrenia drugs
Boehringer Ingelheim has lined up an option on the schizophrenia drugs under development at GSK spinout Autifony, including the lead therapy AUT00206.
Starting with a €25 million upfront fee, with another €17.5 million in near-term milestones, Boehringer agreed to pay up to €627.5 million for global rights to its Kv3 modulators. And after advancing the work on schizophrenia, the partners want to branch out into Fragile X and other CNS ailments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.